Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad26.COV2 S (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Janssen Vaccines and Prevention B.V

    • Most Recent Events

    • 15 Nov 2022 Results of pooled analysis (of cohorts 1a and 3 from the phase 1/2a COV1001 study NCT04436276 and group 5 from the phase 2a COV2001 study NCT04535453) assessing Antibody Persistence After a Single Dose of COVID 19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach published in the Clinical Pharmacology and Therapeutics.
    • 03 Jun 2022 Results of a pooled analysis (NCT04436276 and NCT04535453) assessed the durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boostingpublished in the Vaccine
    • 12 Apr 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top